To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.8949116.
The Japanese government’s current policy is to encourage hospitals to discharge hospital patients with schizophrenia earlier and provide them with community care. This study aims to analyze clinical and economic outcomes of different discharge strategies in psychiatric hospitals in Japan.
A simulation was conducted to compare patient relapse and hospital revenues for different discharge plans. We constructed a decision tree where each tree consists of a different Markov chain that models hospital revenue for four different discharge plans: discharge of the patient after 1, 2, or 3 months, or 4 months or more. The simulation also included variations in the medical treatment regimen in an outpatient setting as part of the discharge strategy. In particular, we looked at the choice between risperidone long-acting injectable (RLAI) and generic risperidone (RIS GE).
The use of RLAI in an outpatient setting reduced the number of rehospitalizations compared to generic risperidone use under all discharge plans. Different discharge plans were associated with differences in economic outcomes as well. One of the key revenue drivers for the hospital was the continuation of treatment in the outpatient setting after discharge.
The use of RLAI in an outpatient setting could help to prevent rehospitalization, thereby contributing to better community care.
The Rapid Service Fee was funded by Janssen KK.
Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399–409. CrossRef
Sado M, Inagaki A, Koreki A, et al. The cost of schizophrenia in Japan. Neuropsychiatr Dis Treat. 2013;9:787–98. CrossRef
Nakamura Y, Mahlich J. Productivity and deadweight losses due to relapses of schizophrenia in Japan. Neuropsychiatr Dis Treat. 2017;13:1341–8. CrossRef
Lin I, Muser E, Munsell M, Benson C, Menzin J. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. J Med Econ. 2014;26:1–11.
Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U. The impact of schizophrenia-related hospital utilization and cost of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585–94. CrossRef
Frey S. The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. Eur Psychiatry. 2014;29(8):479–89. CrossRef
Ministry of Health Labour and Welfare. Individual index of psychiatric care. Tokyo 2011.
OECD. Health data. Paris 2013.
Oshima I, Mino Y, Inmata Y. How many long-stay schizophrenia patients can be discharged in Japan? Psychiatry Clin Neurosci. 2007;61:71–7. CrossRef
Griffiths KM, Nakane Y, Christensen H, Yoshioka K, Jorm AF, Nakane H. Stigma in response to mental disorders: a comparison of Australia and Japan. BMC Psychiatry. 2006;6:21. CrossRef
Kim Y, Berrios GE. Impact of the term schizophrenia on the culture of ideograph: the Japanese experience. Schizophr Bull. 2001;27(2):181–5. CrossRef
Ono Y, Satsumi Y, Kim Y, et al. Schizophrenia: is it time to replace the term? Psychiatry Clin Neurosci. 1999;53:335–41. CrossRef
Kageyama M, Yokoyama K, Nagata S, Kita S, Nakamura Y, Kobayashi S, Solomon P. Rate of family violence among patients with schizophrenia in Japan. Asia Pac J Public Health. 2015;27(6):652–60. CrossRef
Ministry of Health, Labour and Welfare. Summary of a real-world analysis for hospital administration. Tokyo. 2013.
Nakagawa R, Ohnishi T, Kobayashi H, Wakamatsu A, Tanimura A, Morita K, Yamaoka T, Usui H, Ogawa Y, Fujino A, Yoshizawa K. The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:1511–21. PubMedPubMedCentral
Okumura Y, Noda T, Ito H. Antipsychotic prescribing pattern of patients with schizophrenia in Japan: using the national database of health insurance claim information and specified medical checkups. Jpn J Clin Psychopharmacol. 2013;16:1201–15.
Central Social Insurance Medical Council. Report on the psychiatric care. Tokyo 2011.
Marshall D, Burgos-Liz L, IJzerman M, et al. Applying dynamic simulation modeling methods in health care delivery research—the SIMULATE checklist: report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. Value Health. 2015;18:5–16. CrossRef
Zeidler J, Mahlich J, Greiner W, Heres S. Cost-effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Appl Health Econ Health Policy. 2013;11(5):509–21. CrossRef
Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clin Outcomes Res. 2015;7:267–72. CrossRef
Kelly DL. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv. 2001;52(5):676–8. CrossRef
Ministry of Health, Labour and Welfare. Revision of the medical payment system in the area of mental disorder. Tokyo 2014.
Ministry of Health, Labour and Welfare. Information about the drug in the National Health Insurance drug price list and generic drug. Tokyo 2014.
Mahlich J, Roediger-Schluga T. Determinants of pharmaceutical R&D: evidence from Japan. Rev Ind Organ. 2006;28(2):145–64. CrossRef
Central Social Insurance Medical Council. Report on 317th Central Social Insurance Medical Council. 2015.
Yamazawa R, Mizuno M, Nemoto T, Miura Y, Murakami M. Kashima H Duration of untreated psychosis and pathways to psychiatric services in first-episode schizophrenia. Psychiatry Clin Neurosci. 2004;58(1):76–81. CrossRef
The Bank of Japan. Financial and economic monthly report. Tokyo 2015.
Cheung S, Hamuro Y, Mahlich J, Nakahara T, Sruamsiri R, Tsukazawa S. Drug utilization of japanese patients diagnosed with schizophrenia: an administrative database analysis. Clin Drug Investig. 2017;37(6):559–69. CrossRef
Noda F, Clark C, Terada H, Hayashi N, Maeda K, Sato M, et al. Community discharge of patients with schizophrenia: a Japanese experience. Psychiatr Rehabil J. 2004;28(2):143–9. CrossRef
Nemoto T, Niimura H, Ryu Y, Sakuma K, Mizuno M. Long-term course of cognitive function in chronically hospitalized patients with schizophrenia transitioning to community-based living. Schizophr Res. 2014;155(1–3):90–5. CrossRef
Hanzawa S, Bae J, Tanaka H, Bae Y, Tanaka G, Inadomi H, et al. Caregiver burden and coping strategies for patients with schizophrenia: comparison between Japan and Korea. Psychiatry Clin Neurosci. 2010;64(4):377–86. CrossRef
Sruamsiri R, Mori Y, Mahlich J. Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan. J Ment Health. 2019;27(6):583–7. CrossRef
- Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
- Springer Healthcare
Neurology and Therapy
Print ISSN: 2193-8253
Elektronische ISSN: 2193-6536
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II